JP2010502719A5 - - Google Patents

Download PDF

Info

Publication number
JP2010502719A5
JP2010502719A5 JP2009527445A JP2009527445A JP2010502719A5 JP 2010502719 A5 JP2010502719 A5 JP 2010502719A5 JP 2009527445 A JP2009527445 A JP 2009527445A JP 2009527445 A JP2009527445 A JP 2009527445A JP 2010502719 A5 JP2010502719 A5 JP 2010502719A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
alcohol
brain
treatment
ppar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009527445A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010502719A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/019626 external-priority patent/WO2008030604A2/en
Publication of JP2010502719A publication Critical patent/JP2010502719A/ja
Publication of JP2010502719A5 publication Critical patent/JP2010502719A5/ja
Pending legal-status Critical Current

Links

JP2009527445A 2006-09-08 2007-09-10 アルコール誘発性脳疾患の治療、予防および回復 Pending JP2010502719A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84298806P 2006-09-08 2006-09-08
PCT/US2007/019626 WO2008030604A2 (en) 2006-09-08 2007-09-10 Treatment, prevention, and reversal of alcohol-induced brain disease

Publications (2)

Publication Number Publication Date
JP2010502719A JP2010502719A (ja) 2010-01-28
JP2010502719A5 true JP2010502719A5 (https=) 2011-11-10

Family

ID=39157889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009527445A Pending JP2010502719A (ja) 2006-09-08 2007-09-10 アルコール誘発性脳疾患の治療、予防および回復

Country Status (7)

Country Link
US (1) US9308198B2 (https=)
EP (1) EP2061442B1 (https=)
JP (1) JP2010502719A (https=)
KR (1) KR20090066289A (https=)
AU (1) AU2007292883B2 (https=)
CA (1) CA2663121C (https=)
WO (1) WO2008030604A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3788877B1 (en) * 2007-04-11 2024-08-07 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
JP2013194007A (ja) * 2012-03-21 2013-09-30 Cci Corp 抗酸化ストレス剤およびその用途
CA2878402A1 (en) * 2012-07-06 2014-01-09 Omeros Corporation Andrographis paniculata compositions and methods for treatment of addictions
US8865761B1 (en) 2012-08-07 2014-10-21 The University Of Notre Dame Du Lac Regulation of cholesterol homeostasis

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525338A (en) 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US5223242A (en) 1985-11-05 1993-06-29 The General Hospital Corporation Negatively charged specific affinity reagents
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5260308A (en) 1991-11-06 1993-11-09 Mayo Foundation For Medical Education And Research Method to increase permeability of the blood-nerve/brain barriers to proteins
US5620675A (en) 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
US5326770A (en) 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
DE4311651A1 (de) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
US5482698A (en) 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
DE4418965A1 (de) 1994-05-31 1995-12-07 Boehringer Ingelheim Int Verfahren zum Einbringen von Nukleinsäure in höhere eukaryotische Zellen
US5902726A (en) 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US6022897A (en) 1995-04-25 2000-02-08 The Salk Institute For Biological Studies Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
US6413994B1 (en) 1999-02-22 2002-07-02 The Salk Institute For Biological Studies Modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
US5939442A (en) 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
US5958371A (en) 1995-06-08 1999-09-28 Barnes-Jewish Hospital Site specific binding system, nuclear imaging compositions and methods
US5690907A (en) 1995-06-08 1997-11-25 The Jewish Hospital Of St. Louis Avidin-biotin conjugated emulsions as a site specific binding system
US5780010A (en) 1995-06-08 1998-07-14 Barnes-Jewish Hospital Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
US6294559B1 (en) 1996-05-02 2001-09-25 Merck & Co., Inc. Antiproliferative agents associated with peroxisome proliferator activated receptors gamma1 and gamma2
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
AU5811298A (en) 1996-12-31 1998-07-31 Salk Institute For Biological Studies, The Treatment of disease states which result from neoplastic cell proliferation using ppar-gamma activators and compositions useful therefor
US6060515A (en) 1997-01-24 2000-05-09 The Regents Of The University Of California Treatment of skin conditions by use of PPARα activators
US5814647A (en) 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms
US5925657A (en) 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production
AU8355998A (en) 1997-07-24 1999-02-16 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions with cholesterol-lowering effect
US6342507B1 (en) 1997-09-05 2002-01-29 Isotechnika, Inc. Deuterated rapamycin compounds, method and uses thereof
BR9814087A (pt) 1997-10-17 2000-10-03 Aventis Pharm Prod Inc Processos para mediar a atividade do receptor de ppar-gama, e para tratar uma condição fisiológica em um paciente
US6242196B1 (en) 1997-12-11 2001-06-05 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
US6083486A (en) 1998-05-14 2000-07-04 The General Hospital Corporation Intramolecularly-quenched near infrared fluorescent probes
GB9822473D0 (en) 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
US6468996B1 (en) 1998-10-21 2002-10-22 Novo Nordisk A/S Substituted hetero-polycyclic compounds as PPARα and PPARγ activators
GB9824614D0 (en) 1998-11-11 1999-01-06 Glaxo Group Ltd Chemical compounds
US6713514B1 (en) 1999-04-19 2004-03-30 Lexicon Pharmaceuticals, Inc. PPAR-γ agonists as agents for the treatment of type II diabetes
JP4618845B2 (ja) 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体(PPAR)αアゴニストとしての置換フェニルプロピオン酸誘導体
ES2277842T3 (es) 1999-06-18 2007-08-01 MERCK & CO., INC. Derivados de ariltiazolidindiona y de ariloxazolidindiona.
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
GB9919413D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
US6949259B1 (en) 1999-11-11 2005-09-27 Kyorin Pharmaceutical Co., Ltd. Solid preparations for oral use
US6462046B2 (en) 2000-01-06 2002-10-08 Advanced Syntech, Llc Heterocycle derivatives as PPAR-gamma agonists
US6569879B2 (en) 2000-02-18 2003-05-27 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
US6372250B1 (en) 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
WO2001087860A2 (en) 2000-05-12 2001-11-22 Ortho-Mcneil Pharmaceutical, Inc. Novel benzoxazinones as peroxisome proliferator activated receptor gamma modulators and method of treatment
US6908908B2 (en) 2000-05-12 2005-06-21 Ortho-Mcneil Pharmaceutical, Inc. Biologically active 4H-benzo [1,4] oxazin-3-ones
ES2288957T3 (es) 2000-05-12 2008-02-01 Ortho-Mcneil Pharmaceutical, Inc. 4h-benzo(1.4)oxazin-3-ina biologicamente activas.
US7049342B2 (en) 2000-05-29 2006-05-23 Kyorin Pharmaceutical Co., Ltd. Substituted phenylpropionic acid derivatives
CA2417005A1 (en) 2000-07-20 2002-01-31 Bristol Myers Squibb Company Regulators of ppar.delta.(.beta.) and their use in the treatment of obesity and insulin resistance
WO2002008188A1 (en) 2000-07-25 2002-01-31 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
US6787552B2 (en) 2000-08-11 2004-09-07 Nippon Chemiphar Co., Ltd. PPAR delta activators
AU2001292874B2 (en) 2000-09-27 2006-06-15 Merck & Co., Inc. Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
PL366068A1 (en) 2000-10-10 2005-01-24 Smithkline Beecham Corporation Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppar-gamma binding agents
JP2004530408A (ja) 2000-10-19 2004-10-07 ザ ジェネラル ホスピタル コーポレーション 酵素活性の画像化法
JP4350946B2 (ja) 2000-10-31 2009-10-28 メルク エンド カムパニー インコーポレーテッド 糖尿病及び脂質異常症の治療のためのベンゾピランカルボン酸誘導体
UY27003A1 (es) 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US7091225B2 (en) 2000-12-20 2006-08-15 Smithkline Beecham Corporation Substituted oxazoles and thiazoles as hPPAR alpha agonists
WO2002060388A2 (en) 2001-01-30 2002-08-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
AU2002251978B2 (en) 2001-02-09 2007-07-19 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
EP1360172A1 (en) 2001-02-15 2003-11-12 Pfizer Products Inc. Ppar agonists
ITRM20010136A1 (it) 2001-03-16 2002-09-16 Sigma Tau Ind Farmaceuti Composti utili per il trattamento di patologie che rispondono all'attivazione del recettore ppar-gamma.
US6548538B2 (en) 2001-05-22 2003-04-15 Bayer Aktiengesellschaft Propionic acid derivatives
JP2002368028A (ja) 2001-06-13 2002-12-20 Nec Corp 半導体パッケージ及びその製造方法
US6869967B2 (en) 2001-07-30 2005-03-22 Novo Nordisk A/S Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives
JP4179494B2 (ja) 2001-10-23 2008-11-12 株式会社カネカ ペルオキシソーム増殖剤応答性受容体リガンド剤
US20040115127A1 (en) 2002-04-12 2004-06-17 Wright Samuel D. Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
US6673823B2 (en) 2002-06-04 2004-01-06 Cedars-Sinai Medical Center Use of peroxisome proliferator activated receptor (PPAR)-γ ligands as a treatment for pituitary tumors and associated conditions, such as Cushing's syndrome
CA2499380A1 (en) 2002-09-05 2004-03-18 Novo Nordisk A/S Novel vinyl carboxylic acid derivatives and their therapeutical use
US20040224995A1 (en) * 2003-05-09 2004-11-11 University Of North Texas Health Science Center At Fort Worth Neuroprotective effects of PPARy agonists against cellular oxidative insults
US6987118B2 (en) 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
CN1897939A (zh) 2003-10-31 2007-01-17 詹森药业有限公司 适用作过氧化物酶体增生物激活受体(ppar)双重激动剂的苯氧基乙酸衍生物
EP1682507A1 (en) 2003-11-05 2006-07-26 F. Hoffmann-La Roche Ag Benzannelated compounds as ppar activators
ATE557013T1 (de) 2004-03-16 2012-05-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte benzol-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
EP1586573B1 (en) 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolones, processes for their preparation and their use as pharmaceuticals
EP1742923B1 (en) 2004-04-28 2009-05-27 F.Hoffmann-La Roche Ag Pyrazole phenyl derivatives as ppar activators
AU2007299920A1 (en) 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
EP3788877B1 (en) 2007-04-11 2024-08-07 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions

Similar Documents

Publication Publication Date Title
Baron et al. Tolerability, safety, and quality of life with tapentadol prolonged release (PR) compared with oxycodone/naloxone PR in patients with severe chronic low back pain with a neuropathic component: a randomized, controlled, open‐label, phase 3b/4 trial
JP2010502719A5 (https=)
Hurt et al. New pharmacological treatments for the management of obesity
JP2009535425A5 (https=)
US8093299B2 (en) Methods of treating bowel disorders
JP2008509224A5 (https=)
Amin et al. A pilot study of the beneficial effects of amantadine in the treatment of painful diabetic peripheral neuropathy
WO2006055954A3 (en) Steroid formulation and methods of treatment using same
CN105828821A (zh) 具有κ活性的阿片受体拮抗剂和沃替西汀用于治疗具有忧郁特征的抑郁障碍的用途
Fontenot et al. The effects of fluoxetine and buspirone on self-injurious and stereotypic behavior in adult male rhesus macaques
JP2010502718A5 (https=)
US20200188388A1 (en) Methods and compositions for potentiating cns drugs and reducing their side effects
CN102099033B (zh) 用于治疗纤维肌痛症的药物组合物
CN110267657B (zh) 氨基甲酸酯化合物用于预防、缓解或治疗震颤或震颤综合征的用途
Chiche et al. (420) NEO6860, a novel modality selective TRPV1 antagonist: results from a phase I, double-blind, placebo-controlled study in healthy subjects
EP2167080A1 (en) Pharmaceutical formulation comprising pramipexole
Noon et al. (418) A novel glial cell inhibitor, low dose naltrexone, reduces pain and depression, and improves function in chronic pain: A CHOIR study
RU2654713C1 (ru) Фармацевтическая композиция, содержащая комбинацию мемантина и мелатонина
Rusinova et al. P. 6.047 Non-steroidal anti-inflammatory drugsin the treatment of opiate withdrawal syndrome
ÜSTÜN PSYCHOTROPIC DRUGS AND THEIR IMPACT ON ORAL HEALTH
JP6753661B2 (ja) 止瀉剤組成物
HK40015061A (en) Use of carbamate compounds for preventing, alleviating, or treating tremors or tremor syndrome
Rousseaux et al. Preclinical evaluation of intestinal anti-inflammatory/analgesic properties and phase I clinical trial of a new PPAR Agonist Ged-0507-34-Levo
HK40015061B (en) Use of carbamate compounds for preventing, alleviating, or treating tremors or tremor syndrome
BR112019012000B1 (pt) Uso de um composto de carbamato